Go to the profile of Lightchain Bio

Lightchain Bio

CEO, Light Chain Bioscience
  • Light Chain Bioscience
  • +4155 5667500
  • Networkers
  • Switzerland

About Lightchain Bio

Multispecific antibodies, including bispecific, can only meet their full potential if they are well tolerated by the human body. As such, Light Chain Bioscience has taken advantage of the unique features of human antibody light chains and developed an approach to generate bispecific antibodies that retain the full human sequence and architecture of human antibodies. This format, therefore, is ideally suited for therapeutic application, in particular if prolonged administration to patients is required. Our expertise in bispecific antibodies for CD47 targeting is leading the field in approaches to selectively and safely target the immune checkpoint to the tumor microenvironment. We welcome the opportunity to discuss with partners enticed by the use of multipsecific antibody approaches for cancer, including T cell retargeting, as well as other approaches outside oncology.

Therapeutic Areas

Autoimmune disorders Oncology Immuno-Oncology

Technologies

Antibodies

Company Type

Biotechnology – R&D services Biotechnology – Therapeutics Life Sciences

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

March 2020